Dermorphin

What dermorphin is

In 1981, the working group led by Vittorio Erspamer isolated a peptide with seven amino acids from the skin of the frogs Phyllomedusa sauvagei and Phyllomedusa rhodei and determined its sequence: Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2. What is remarkable is the second position: D-alanine, a mirror-image amino acid that practically does not occur in animal proteins. It protects the peptide from rapid breakdown by enzymes and helps explain why the effect lasts a long time.

Dermorphin binds very selectively to the mu-opioid receptor. In the scientific literature on doping analysis, it is described as 30 to 40 times more potent than morphine. This figure is not a mark of quality but the reason why this is a substance with a narrow safety margin.

In the biohacking and forum world, the substance circulates as a research chemical and under the term that comes from horse racing. Chemically, the substance has little to do with the Kambo rituals, in which the skin secretion of another frog is used, even though both come from the same frog family.

How it works

The mu-opioid receptor is the receptor through which the body’s own endorphins, morphine and fentanyl act. When it is activated, pain transmission in the spinal cord is dampened, hormonal axes are shifted, and the respiratory drive in the brainstem falls – all together, not separable at will.

That this chain also runs via opioid receptors with dermorphin has been tested in humans: the antagonist naloxone completely abolished the hormonal effects. In inhibiting a pain reflex, naloxone was only about half effective, which the authors interpreted in 1986 as an indication of several receptor populations being involved.

Animal experiments also revealed the other side of opioid pharmacology: with continuous administration into the brain of rats, tolerance developed within two days, and after three days a physical dependence whose withdrawal syndrome could be triggered with naloxone and corresponded to that of morphine.

What the studies show

The 1985 study that nobody read

Basso and colleagues compared three methods of postoperative pain treatment in 150 consecutive patients, randomized and double-blind. Dermorphin performed best on the duration of freedom from pain. A 2018 review notes that this paper was practically never cited in the clinical literature: after 1985 it was mentioned by only around 15 pharmacological papers and reviews, not a single clinical one. The authors of the review consider this a missed opportunity for pain and palliative medicine and call for new studies – this is explicitly not a verdict on the substance for self-administration.

Pain reflex and hormones in healthy people (1983 to 1986)

The group led by Degli Uberti in Ferrara studied dermorphin systematically in healthy volunteers, partly against saline infusion in random order. The findings paint a typical opioid picture with effects on pituitary hormones and the adrenal axis. Sandrini and colleagues added the neurophysiological part in 1986 with the inhibition of the spinal flexion reflex. All these experiments ran under clinical monitoring in hospitals.

Tolerance and dependence in animal experiments (1985)

Broccardo and colleagues gave rats dermorphin into the brain via implanted pumps. Tolerance to analgesia, catalepsy and rigidity developed dose-dependently over a maximum of 48 hours; after three days a state of dependence was established, whose withdrawal could be triggered with naloxone and showed itself in escape behavior, tremor, salivation and runny nose.

Horse racing from 2011

From 2011, reports from North American racetracks indicated that dermorphin was being used in racehorses without being detected in the controls. In 2013 the first detection method for horse plasma and urine appeared. A study in 10 horses then described the pharmacokinetics and the effect: after intravenous administration, excitement and a rise in heart rate occurred, which subsided after a few minutes; the half-life was under one hour, and the substance was detectable in plasma for up to 12 hours and in urine for 48 to 72 hours. In 2020 a method for human urine followed, with the note that use in humans had been reported.

Where the data stop

There is exactly one controlled human study; it is 41 years old, was never repeated and concerned the treatment of acute pain in hospital. After that, development ended. There is no registry entry, no modern dose–response study, no long-term observation and no pharmacovigilance.

This means that everything that would say something about the safety of use outside the hospital is missing: how large the gap is between the analgesic and the respiratory-depressant effect, how the substance behaves with repeated administration, what it does together with sedatives, alcohol or other opioids. That the side effects in the 1985 study were not more frequent than with morphine is no carte blanche: treatment there took place under anesthesia and monitoring conditions.

There are no data on use in healthy people, for performance enhancement or for mood elevation. What circulates about this comes from anecdotal reports and from extrapolating animal findings.

Status, approval and legal

Dermorphin is not an approved medicine in Germany, the EU or the US. It is not listed in Schedules I to III of the German Narcotics Act (Betäubungsmittelgesetz), nor is it covered by the substance groups of the New Psychoactive Substances Act, which describe basic chemical structures such as phenethylamines, tryptamines or benzimidazoles – a peptide does not fall under these. It is therefore not a narcotic in the legal sense.

That does not make it freely available. A substance intended or offered for the treatment of pain is a medicine under pharmaceutical law, and placing a medicine on the market without approval is a criminal offense under the German Medicines Act. Dermorphin is therefore offered as a research chemical with the note that it is not intended for use in humans.

In sport it is prohibited at all times. It is not named on the 2026 Prohibited List: the narcotics list of group S7 includes buprenorphine, fentanyl and its derivatives, morphine, oxycodone, tramadol and others, but not dermorphin. Instead, it falls under group S0, which covers pharmacologically active substances without approval for therapeutic use in humans. In horse racing it is considered a doping agent with its own testing procedures.

Safety

The risks are those of a highly potent opioid, and they are not theoretical: respiratory depression, clouding of consciousness, nausea, vomiting, urinary retention, constipation, itching. Tolerance and physical dependence develop quickly, in animal experiments within a few days. The danger grows with every combination with other depressant substances, that is, with alcohol, benzodiazepines, sleeping pills and other opioids.

On top of this comes the particular situation of a substance that exists only as a laboratory product: content, purity and sterility are untested, and with a substance that acts many times more potently than morphine at the receptor, a deviation in concentration has different consequences than with a food supplement.

Severe or chronic pain belongs in medical treatment. There, approved opioids are available whose effect can be controlled and whose administration is monitored, along with antidotes for emergencies. Anyone who is dependent on opioids or is going through withdrawal can find help through addiction counseling services and family doctors; opioid dependence is treatable.

Sources

• Montecucchi et al., Int J Pept Protein Res 1981 – amino acid sequence of dermorphin from Phyllomedusa sauvagei
• Basso et al., Peptides 1985 – randomized double-blind trial on postoperative pain treatment, 150 patients
• Sandrini et al., Brain Res 1986 – dermorphin inhibits the spinal pain reflex in humans
• Degli Uberti et al., Peptides 1985 – hormonal effects of dermorphin in healthy people
• Broccardo et al., Eur J Pharmacol 1985 – tolerance and physical dependence in rats
• Keppel Hesselink and Schatman, J Pain Res 2018 – dermorphin as a forgotten drug (review)
• Guan et al., Anal Bioanal Chem 2013 – detection in horse plasma and urine, potency and abuse in racing
• Robinson et al., J Vet Pharmacol Ther 2015 – pharmacokinetics and effect in 10 horses
• Castro et al., J Mass Spectrom 2020 – detection method for human urine in doping control
• NADA – Prohibited List 2026, informational German translation (groups S0 and S7)